MedTrace Logo

An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

NCT06849778 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-05-15

No results posted yet for this study

Summary

A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis

Conditions

  • Patients on Hemodialysis

Interventions

DRUG

TS-172

oral administration of TS-172 20 mg

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-22
Primary Completion
2025-04-24
Completion
2025-04-24

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06849778 on ClinicalTrials.gov